JAAD Publishes Retrospective Study on Dupilumab for Trichoteiromania

The Journal of the American Academy of Dermatology will publish, in its November 2026 issue (Volume 95, Issue 5), a retrospective study evaluating dupilumab for pruritus-driven trichoteiromania in patients with an atopic background.

The study comes from a ten-author team led by Ke Cheng, with co-authors Jiayi Wang, Sichong Tang, Jui-Ming Lin, Linxia Shen, Xiao Liu, Yue Zhang, Qingmei Liu, Wenyu Wu, and Jinran Lin.

Why trichoteiromania?

Trichoteiromania — compulsive rubbing of the hair shafts until they break — sits among the body-focused repetitive behaviors, and when itch is the driver, clinicians face a treatment gap. Antihistamines and topical agents often fall short when the underlying engine is atopic pruritus rather than a primary psychiatric impulse.

That framing is the study's premise: if the itch circuit in atopic disease feeds the rubbing behavior, then blocking IL-4 and IL-13 signaling with dupilumab could interrupt the loop at its dermatologic root.

What does this change for clinicians?

For now, it signals a growing willingness to test biologic therapy in behavior-driven hair disorders when an atopic phenotype is documented. A retrospective design means the findings are hypothesis-generating, not practice-changing on their own — but they add to the widening list of pruritus-associated conditions where dupilumab is being interrogated beyond approved atopic dermatitis indications.

Derm Field will follow the study's efficacy data and any investigator commentary as the November 2026 issue reaches readers.